Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00972075 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects
A Phase 2 study of Blindness and Non-24 Hour Sleep-Wake Disorder, sponsored by Neurim Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
- 2
- Study locations
NCT00972075 is a Phase 2 study of Blindness and Non-24 Hour Sleep-Wake Disorder that has completed, run by Neurim Pharmaceuticals. The registered enrollment target is 13 participants, below the 57-participant average among 7 other Blindness trials with a reported enrollment target (77% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT00972075, a Phase 2 study of Blindness and Non-24 Hour Sleep-Wake Disorder, has completed, sponsored by Neurim Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
- 2
- Study locations
Study Summary
The aim of this placebo-controlled randomized study was to evaluate the efficacy of Circadin™ 2 mg in improving total night sleep duration and stabilizing the circadian clock phase in totally blind subjects with non-24 hour sleep-wake disorder.
Conditions Studied
Interventions
- DRUG placebo
- DRUG melatonin (Circadin)
Study Locations (2)
Georgia
- Sleep Disorders Center of Atlanta - Atlanta
New York
- Clinlabs, Inc. - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2006-02 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00972075
The ClinicalTrials.gov registry entry for NCT00972075 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 57-participant average among 7 other Blindness trials with a reported enrollment target (77% lower). The listed sponsor is Neurim Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Blindness appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00972075 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Georgia, New York.
Frequently Asked Questions
What is clinical trial NCT00972075 about?
NCT00972075 is a clinical study titled "Efficacy and Safety of Circadin for Non-24 Hour Sleep-Wake Disorder in Totally Blind Subjects". The aim of this placebo-controlled randomized study was to evaluate the efficacy of Circadin™ 2 mg in improving total night sleep duration and stabilizing the circadian clock phase in totally blind subjects with non-24 hour sleep-wake disorder.
What is the current status of trial NCT00972075?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2006-02. Estimated completion is 2007-10.
What conditions does trial NCT00972075 study?
This clinical trial studies the following conditions: Blindness, Non-24 Hour Sleep-Wake Disorder.
What interventions are being tested in trial NCT00972075?
The interventions under investigation include: placebo (DRUG), melatonin (Circadin) (DRUG).
Who is sponsoring clinical trial NCT00972075?
This trial is sponsored by Neurim Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00972075 being conducted?
This trial has 2 study locations across Georgia, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Blindness
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE)
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
RECRUITING · Phase 3
-
Testing Tactile Aids With Blind Subjects
RECRUITING · NA
-
Enhanced Tactile Memory in the Blind
COMPLETED
-
Brain Plasticity of Verbal Memory in the Blind
COMPLETED
-
A Study to Evaluate the BrainPort® Vision Device in Subjects Who Are Blind
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.